Medication Monitor

Generic Name (Trade Name—Company)
May 1, 2011


Treatment of pancreatic tumors


Treatment of patients with progressive neuroendocrine tumors located in the pancreas that are unresctable, locally advanced, or metastatic

Approval was based on data from a randomized, double-blind, multicenter trial that compared use of everolimus 10 mg once daily plus best supportive care (n = 207) versus placebo plus best supportive care (n = 203) in patients with disease progression within the previous 12 months. Treatment with everolimus resulted in a statistically significant improvement in investigator-determined progression-free survival compared with placebo (median 11.0 vs. 4.6 mo).